 NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 12 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology ASCO20 Annual Meeting. Because this is a trial in progress with limited samples, we cannot draw definitive conclusions, but we believe these early biomarker data provide additional evidence of NC318 activity, said Kevin N. Heller, M.D., NextCures chief medical officer. 